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ABSTRACT
Introduction: In the last 20 years, biologic and
targeted synthetic disease-modifying antirheu-
matic drugs (DMARDs) have become available
for treating rheumatoid arthritis (RA), and a
treat-to-target strategy has been introduced. We
hypothesise that these advances should have
resulted in changes to the characteristics of
patients with RA participating in clinical trials
of the newest therapies. This study determined
whether the baseline characteristics of patients
with RA enrolled in clinical trials have changed
in the past decade versus patients participating
in earlier RA studies.
Methods: This secondary analysis was based on
randomised controlled trials (RCTs) identified
in a systematic literature review. Baseline char-
acteristics of patients with RA with inadequate
response to conventional synthetic DMARDs
were compared between RCTs published in
1999–2009 and those published in 2010–2017
using random-effects meta-analyses.
Results: Forty RCTs were analysed: 22 from
1999–2009 and 18 from 2010–2017. No signifi-
cant difference between the two timeframes and
no obvious trend over time were observed for
age, gender, disease duration, rheumatoid factor
status, tender and swollen joint counts, physi-
cian and patient global assessments of disease
activity, and pain scores. Variability between
RCTs was high. Similar results were observed for
Disease Activity Scores and Health Assessment
Questionnaire-Disability Index scores, but with
low variability between RCTs.
Conclusion: The baseline characteristics of
patients with RA participating in RCTs do not
appear to have changed in the last decade
despite the availability of new treatments and a
different treatment approach. Further research
should determine the impact of baseline patient
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characteristics on patients’ response to RA
treatments.
PLAIN LANGUAGE SUMMARY
In the last 20 years, new treatments and a new
treatment approach (called treat-to-target) have
been introduced for rheumatoid arthritis (RA).
Consequently, the characteristics of patients
with RA participating in clinical trials of the
newest therapies should have changed com-
pared with those of patients who participated in
clinical trials of older therapies. This is impor-
tant as patient characteristics may influence
patients’ response to drug treatment. To deter-
mine whether characteristics of patients with
RA have changed over time, we compared the
baseline characteristics (e.g. age, gender, disease
duration, measures of disease activity, and pain
scores) of patients with RA between 22 clinical
trials published in 1999–2009 and 18 published
in 2010–2017. No significant difference
between the two timeframes and no obvious
trend over time were observed for any baseline
characteristic of patients with RA, including
physician and patient measures of disease
activity, and patient measures of physical
function and pain. Thus, the baseline charac-
teristics of patients with RA participating in
clinical trials do not appear to have changed in
the last decade despite the introduction of new
treatments and the treat-to-target approach.
Further research is needed to determine the
impact of baseline patient characteristics on
patients’ response to RA treatments.
Keywords: Disease-modifying antirheumatic
drugs; Patient characteristics; Randomised
controlled clinical trials; Rheumatoid arthritis;
Rheumatology; Systematic review
Key Summary Points
Why carry out this study?
The introduction of new treatments and a
treat-to-target strategy for rheumatoid
arthritis (RA) in the last 20 years should
have resulted in changes to the
characteristics of patients with RA
participating in clinical trials of the
newest therapies.
This is important as patient characteristics
may influence patients’ response to drug
treatment.
To determine whether characteristics of
patients with RA have changed over time,
baseline characteristics were compared
between 22 clinical trials published in
1999–2009 and 18 published in
2010–2017.
What was learned from the study?
No significant difference between the two
timeframes and no obvious trend over
time were observed for any baseline
characteristic of patients with RA,
including physician and patient
assessments of disease activity, and Health
Assessment Questionnaire-Disability
Index and pain scores.
The baseline characteristics of patients
with RA participating in clinical trials do
not appear to have changed in the last
decade; further research is needed to
determine the impact of baseline patient
characteristics on patients’ response to RA
treatments.
INTRODUCTION
Rheumatoid arthritis (RA) is a chronic, autoim-
mune, inflammatory arthritis associated with
pain, disability and an increased risk of mor-
tality [1–3]. Globally, the prevalence of the
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disease is in the range 0.5–1.1% [4, 5]. Con-
ventional synthetic disease-modifying anti-
rheumatic drugs (csDMARDs), such as
methotrexate, leflunomide and sulfasalazine,
provided the standard of care for RA for many
years. However, the choice of treatments for the
disease has expanded over the last 20 years with
the introduction of biologic DMARDs
(bDMARDs), such as abatacept, adalimumab,
certolizumab pegol, etanercept, golimumab,
infliximab, rituximab, sarilumab and tocilizu-
mab, and, more recently, targeted synthetic
(ts)DMARDs, such as baricitinib and tofacitinib.
Guidelines for the management of RA from
the European League Against Rheumatism
(EULAR) and the American College of
Rheumatology (ACR) recommend early use of
DMARDs, with the goal of remission or low
disease activity [6, 7]. This treat-to-target
approach, first introduced in 2010 [8], has
improved the care and outcomes of patients
with RA [9, 10]. However, several studies suggest
that many patients with RA are not reaping the
benefits of this treat-to-target approach or the
benefits derived from newer DMARDs because
of underuse of these drugs. A review of data
from the US National Ambulatory Care Medical
Survey over a 12-year period (1996–2007)
showed that only 47% of visits to a physician
for RA were associated with a DMARD pre-
scription [11], while a later retrospective review
of data over a 3-year period (2005–2008)
showed that only 63% of 93,143 Medicare
enrollees with RA in the USA received a
DMARD. Prescribed DMARDs varied with
demographic factors, socioeconomic status and
geographic location. Cited reasons for the low
proportion of DMARD prescriptions included
low income, for-profit health plans, patients
refusing treatment and increased comorbidities
in the elderly resulting in contraindications to
available drugs [12].
A systematic review of 127 studies of patients
with RA highlighted significant differences in
certain patient characteristics, including age,
disease duration, number of DMARDs previ-
ously used and Disease Activity Score for
28-joint count (DAS28), between patients
enrolled in randomised controlled clinical trials
(RCTs) and those enrolled in registries [13]. In
addition, baseline DAS28 and Health Assess-
ment Questionnaire-Disability Index (HAQ-DI)
scores for patients with RA prescribed
bDMARDs (etanercept, rituximab or tocilizu-
mab) decreased over time for RCTs and obser-
vational studies published between 2004 and
2014 [13], probably owing to the introduction
of the treat-to-target strategy during this period
[14]. This trend was consistent with the results
of an observational study conducted in the
Netherlands, in which symptom duration and
inflammatory activity at presentation were
found to have decreased over a 23-year period
(1993–2015) among patients with RA attending
a local rheumatology department. Paradoxi-
cally, however, patient-reported outcomes
(pain, fatigue, disease activity and global
health) worsened over this time period, possibly
as a result of increased societal and patient
expectations [10].
Given the change in treatment strategy and
the introduction of new DMARDs with different
mechanisms of action in recent years (e.g. the
Janus kinase inhibitors baricitinib and tofaci-
tinib, and the interleukin-6 inhibitor sar-
ilumab), the characteristics of patients
participating in RA clinical trials might be
expected to have changed over time. This is
important as patient characteristics may influ-
ence the effects of drug treatment [13].
According to data from the systematic literature
reviews (SLRs) conducted by Kilcher et al. [13],
the characteristics of patients with RA enrolled
in RCTs who show an inadequate response to
csDMARDs might be expected to change over
time, and this may influence the rate of
response to new treatments as well as making it
difficult to compare drugs evaluated during
different time periods. To date, however, no
such analysis has been published. To address
this important issue and inform the design of
future RCTs evaluating new RA treatments, we
conducted a study to determine whether the
baseline characteristics of patients with RA with
an inadequate response to csDMARDs partici-
pating in RCTs between 1999 and 2017 have
changed over time.
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METHODS
Objective
This study aimed to compare the characteristics
of patients with an inadequate response to
csDMARDs participating in RA RCTs between
two different, predefined timeframes–an earlier
timeframe (1999–2009) when bDMARDs were
first introduced, and a later timeframe
(2010–2017) after the introduction of treat-
ments with different mechanisms of action and
adoption of the treat-to-target strategy.
Systematic Literature Review
This secondary analysis was based on the results
of a previously conducted SLR [15]. The SLR
aimed to identify evidence for the efficacy and
safety of treatments for moderately to severely
active RA in adults. Searches of Medline, Med-
line in Process, Embase, Biosciences Informa-
tion Service and the Cochrane Library were
performed to identify RCTs published between
1 January 1999 and 11 December 2017 using
search terms related to RA, associated inter-
ventions and RCTs (Table S1 in the supple-
mentary material). The original searches were
performed on 17 June 2015 and updated sear-
ches were performed on 10 August 2016 and
11 December 2017. There were no language
limits on the database searches. Conference
abstracts (2013–2017), grey literature and the
bibliographies of key articles were also reviewed.
Data were extracted from relevant full-
text publications and quality-checked by an
independent reviewer. The quality of each study
was also assessed using National Institute for
Health and Care Excellence (NICE) guidelines
[16]. The SLR was conducted according to Pre-
ferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) guidelines [17].
Current Analysis
The analysis reported here focused on studies
from the SLR involving patients with an
inadequate response to csDMARDs, including
methotrexate, hydroxychloroquine, leflunomide
andsulfasalazine.As such, themainanalysis study
poolonly included studies thatdidnotallowprior
bDMARD use. The following baseline patient
characteristics of interest extracted from the
studies were analysed: age, gender, disease dura-
tion, rheumatoid factor status, DAS28 based on
erythrocyte sedimentation rate (DAS28-ESR) or
C-reactive protein (DAS28-CRP), HAQ-DI score,
swollen joint count (SJC), tender joint count
(TJC), Physician’s Global Assessment of Disease
Activity (PGA), Patient’s Global Assessment of
DiseaseActivity (PtGA), painvisual analogue scale
(VAS) score, previous use of non-steroidal anti-
inflammatory drugs (NSAIDs) and number of
previously used csDMARDs.
Additional baseline characteristics that were
extracted from the studies but could not be
analysed because of lack of or limited data
availability included weight, comorbidities,
smoking status, Clinical Disease Activity Index
(CDAI) and Simplified Disease Activity Index
(SDAI) scores, Routine Assessment of Patient
Index Data-3 (RAPID-3) score, erosion score,
joint space narrowing score, van der Heijde
modified total Sharp score (mTSS) and Euro-
QoL-5 Dimensions (EQ-5D) questionnaire score.
The analysis reported in this article is based
on previously conducted studies and does not
involve any studies with human participants or
animals performed by any of the authors.
Statistical Analysis
If not already presented as such, baseline
patient characteristics from different treatment
arms within a given study were combined into
an overall study result. Where necessary, medi-
ans and ranges from each study were converted
to means and standard deviations using the
methods of Wan et al. [18]. For binary data, the
variance estimate (v) for proportions (p) was
used to derive the standard error using the for-
mula v = p(1 - p). The results from the various
studies were compared between the two study
publication timeframes (1999–2009 vs
2010–2017) using random-effects meta-analy-
ses. Between-study variance was assessed using
restricted maximum-likelihood estimation and
was presented as an I2 value, showing the
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proportion of the observed variance that reflects
real difference between studies (i.e. it is not due
to random error), where higher percentages
represent higher variance; and a Tau-squared
value, showing between-study variation, where
higher values represent higher variation. The
level of significance was taken as p B 0.05
(unadjusted for multiple testing). Missing data
were not imputed for this analysis. Forest plots
were generated for all analyses, with study
results ordered by year of publication to provide
a visual display of potential changes over time.
Analyses were conducted using SAS version 9.4,
R studio version 3.4, and metafor package ver-
sion 2.0 [19].
Sensitivity Analyses
Two sensitivity analyses were performed to
assess the effect of changing the patient popu-
lation on results. One sensitivity analysis
excluded Asia–Pacific studies, since patients
from these countries (mainly Japanese) were
likely to have been treated with a low dose of
methotrexate (\7.5 mg/week), which could
potentially impact the extent of methotrexate
failure among trial populations. In addition to
studies included in the main analysis, the sec-
ond sensitivity analysis included studies that
allowed prior bDMARD use in up to 20% of
patients, since patients receiving bDMARDs
were more likely to be further advanced in the
RA treatment algorithm. The value of 20% was
selected as many studies allowing some prior
use of bDMARDs cited this value as the cut-off.
RESULTS
Study Numbers
A total of 147 primary studies including patients
with an inadequate response to csDMARDs were
identified in the SLR, of which 94 were excluded
(Fig. 1). Of the remaining 53 studies, 13 allowed
prior use of bDMARDs in up to 20% of patients
and were consequently excluded from the main
analysis. Thus, the main analysis included a total
of 40 studies. Of these, 22 were published in the
earlier timeframe and 18 in the later timeframe.
The 13 studies allowing prior use of bDMARDs in
up to 20% of patients were combined with the 40
studies from the main analysis into a sensitivity
analysis; details of these 53 studies are provided in
Table S2 in the supplementary material [20–72].
Treatments evaluated in the studies included
csDMARDs (hydroxychloroquine, methotrexate,
sulfasalazine), bDMARDs (abatacept, adalimumab,
certolizumab pegol, etanercept, golimumab,
infliximab, rituximab, sarilumab, tocilizumab),
and tsDMARDs (baricitinib, tofacitinib). Not all
identified studies were included in each specific
characteristic analysis as some did not report
relevant information or reported data in a man-
ner thatdidnot allowdata tobeconverted (e.g. to
means and standard deviations).
Main Analysis
There was no statistically significant difference
between the two timeframes and no obvious
trend over time for age, gender, disease duration
(mean difference between timeframes approxi-
mately 1 year), rheumatoid factor status, PGA,
PtGA and pain VAS scores (Figs. 2 and S1).
However, there was high variability (hetero-
geneity) between studies. Similarly, there was
no statistically significant difference between
timeframes and no obvious trend over time for
DAS28-ESR, DAS28-CRP and HAQ-DI scores; in
these cases, heterogeneity was low (Fig. 3). SJC
(score range 0–66) and TJC (score range 0–68)
were not significantly different between time-
frames and there was no obvious trend over
time; heterogeneity was also high. Different
inclusion criteria were observed between studies
for the minimum number of swollen or tender
joints. We therefore conducted further analyses
focusing on the minimum number of swollen or
tender joints used as the inclusion criterion in
each study, and on the most common inclusion
criteria for minimum number of swollen and
tender joints (B 6 for SJC, B 6 and C 8 for TJC).
However, this did not change the results to any
great extent (Figs. 4 and S2).
Information on the number of csDMARDs
previously used was not reported in a unified
manner, with very few studies (n = 3 in
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Duplicates excluded  n = 6,130  
LEVEL 2 SCREEN
(Full texts screened)
n  = 962
Records idenfied through 
database searches 
n = 14,632
Total records idenfied aer eliminaon of duplicates
n = 10,008
(Database searches = 8,517; Internet searches = 1,458; Hand searches = 33)
Records idenfied 
through Internet searches 
n = 1,473
LEVEL 1 SCREEN
(Titles/abstracts screened)
n = 10,008
Records idenfied through 
hand searches 
n = 33
Total records included in systemac 
review  n = 322 
(Total studies n = 147)
Records excluded n = 94
Study type n = 5
Paent populaon n = 56
Intervenon n = 22
Outcomes n = 5
Other n = 6Studies of paents with inadequate 
response to MTX or other csDMARD 
n = 53
Studies included in main analysis 
n = 40 
Records excluded n = 13
Studies allowing prior bDMARD use in up to 
20% of paents were included in a 
sensivity analysis
Fig. 1 PRISMA diagram for study identification. bDMARD, biologic DMARD; csDMARD, conventional synthetic
DMARD; DMARD, disease-modifying antirheumatic drug; MTX, methotrexate
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1999–2009; n = 5 in 2010–2017) providing
means and standard deviations. For studies
providing the latter, a statistically significant
difference between timeframes was observed
with low to moderate heterogeneity (I2 33%,
Tau2 0.06, p\ 0.001; Fig. S3). The remaining
studies either did not report this information or
reported categories, which could not be con-
verted into means and standard deviations. For
prior NSAID exposure, most studies (24 out of
28; 86%) reported NSAID use in 100% of
patients; therefore, no meta-analysis was run.
Sensitivity Analyses
The sensitivity analysis excluding Asia–Pacific
studies included 28 studies: 16 from the earlier
timeframe and 12 from the later timeframe. The
results of this analysis were consistent with
those of the main analysis (Fig. S4).
The sensitivity analysis allowing prior use of
bDMARDs in up to 20% of patients included 53
studies: 26 from the earlier timeframe and 27
from the later timeframe. Again, the results of
this analysis were consistent with those of the
main analysis (Fig. S5).
DISCUSSION
With the introduction of the treat-to-target
strategy in RA and the availability of new
treatments, the inclusion criteria for RA clinical
trials might be expected to have changed in the
past decade. However, the results of our analysis
suggest that this is not the case: the character-
istics of patients participating in recent clinical
trials do not appear to have changed compared
with those of patients participating in RCTs
10–20 years ago.
Patient characteristics are an important
consideration in clinical trials as they may
influence the effects of treatment. For example,
older age is associated with decreased response
rates in patients treated with etanercept or
tocilizumab [73, 74], while male sex, being
rheumatoid factor-positive, having a low HAQ-
DI score and being a non-smoker predict a bet-
ter response to various bDMARDs [73, 75, 76].
In addition, a study comparing the baseline
characteristics of patients with RA between
RCTs and observational studies showed that
patients participating in RCTs had better prog-
nostic factors than those participating in
observational studies, which could result in
overestimation of the treatment effect [13].
In this analysis, the lack of a change in
DAS28 and HAQ-DI scores at baseline between
the two timeframes was surprising given that
real-world data from registries or observational
studies suggest that baseline disease activity
among patients with RA has decreased over
time [77–79]. In addition, the aforementioned
study by Kilcher et al. [13] comparing the
baseline characteristics of patients with RA
between RCTs and observational studies
showed that baseline DAS28, HAQ-DI, ESR and
CRP significantly decreased in patients partici-
pating in RCTs over the time period 1999–2015.
An SLR of patients with RA receiving anti-tu-
mour necrosis factor treatment in clinical trials
over a 16-year period (1993–2008) showed a
similar decrease in baseline CRP over time
among patients previously treated with
methotrexate but not among those with no
experience of this drug [80]. However, the cur-
rent analysis suggests that baseline disease
activity among patients with RA participating in
RCTs has not decreased over time, possibly
because patients participating in RCTs tend to
have more severe disease at baseline than those
in routine clinical practice [13, 81]. The lack of
change in disease activity in the current analysis
may also be due to barriers in adopting the
treat-to-target strategy in clinical practice com-
pared with clinical trials, such as a lack of
physician understanding of this treatment
strategy, the feeling that the disease activity
score may be falsely high due to symptoms or
inflammation unrelated to RA, physician resis-
tance to algorithm-based treatment, or a lack of
time at clinic visits [82–84]. The lack of change
in baseline disease activity over time likely
reflects a lack of change in the strict inclusion
criteria for patients participating in an RCT. In
view of this, different methodology to that used
in our analysis and measurement of different
clinical/laboratory parameters might be neces-
sary to detect any change over time in patient
3682 Adv Ther (2020) 37:3676–3691
characteristics; this could be a subject for future
research.
This analysis suggests that the mean number
of previously used csDMARDs in patients par-
ticipating in RCTs has decreased over time,
possibly reflecting adoption of the treat-to-tar-
get approach. However, this result was based on
only a few studies and was not observed in the
sensitivity analysis that included studies allow-
ing prior bDMARD use in up to 20% of patients.
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(a) Physician's Global Assessment of Disease Activity (scale 0−100)
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(b) Patient's Global Assessment of Disease Activity (scale 0−100)
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(c) Pain visual analogue scale (scale 0−100)
Fig. 2 Forest plots showing means and 95% confidence
intervals (CI; box and whisker plots) for the different
studies according to year of publication for a Physician’s
Global Assessment of Disease Activity score, b Patient’s
Global Assessment of Disease Activity score and c Pain
Visual Analogue Scale score. If studies reported pain on a
scale of 0–10, values were multiplied by 10. I2 and Tau2
values indicate a high degree of heterogeneity between
studies, while p values indicate no significant difference in
mean values between studies published from 1999 to 2009
(studies above dashed line) and those published from 2010
to 2017 (studies below dashed line). Diamond shapes
indicate 95% confidence intervals around the means
summarised by timeframe and overall, respectively
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This suggests that it was either a ‘chance find-
ing’ based on a small number of studies or that
the inclusion of patients with prior bDMARD
use corresponded to the inclusion of patients
with more severe disease and hence a higher
number of previously used csDMARDs, which
would have diluted the effect over time. Very
few studies reported the mean number of pre-
viously used csDMARDs: most reported previ-
ous csDMARD use as the percentage of patients
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(a) DAS28 based on erythrocyte sedimentation rate
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(b) DAS28 based on C−reactive protein
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(c) Health Assessment Questionnaire−Disability Index score (scale 0–3)
Fig. 3 Forest plots showing means and 95% confidence
intervals (CI; box and whisker plots) for the different
studies according to year of publication for a Disease
Activity Score for 28-joint count (DAS28) based on
erythrocyte sedimentation rate, b DAS28 based on
C-reactive protein and c Health Assessment Question-
naire-Disability Index score. Diamond shapes indicate 95%
confidence intervals around the means summarised by
timeframe and overall, respectively. I2 and Tau2 values
indicate a low degree of heterogeneity between studies,
while p values indicate no significant difference in mean
scores between studies published from 1999 to 2009
(studies above dashed line) and those published from 2010
to 2017 (studies below dashed line)
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using a certain number (e.g. 1, C 1, C 2, etc.),
which could not be used in the current analysis.
Thus, no definitive conclusions about previous
csDMARD use can be drawn.
RCTs are very different to real-world clinical
practice in that patients who are eligible for
clinical trials generally have more severe disease
[81]. Results of the current analysis suggest that
patients currently being enrolled in RA RCTs are
not receiving the correct treatment before
commencement of the study. Although treat-
to-target is the recommended approach for the
management of RA [6, 7], RCTs are still being
performed in which none of the participating
patients have been treated accordingly. This
begs the question as to whether RCTs are as
informative as they were 15 years ago. In future,
it would be interesting to design RCTs that
include patients who have been treated
according to treat-to-target recommendations.
To our knowledge, this is the first study to
investigate changes over time in the character-
istics of patients enrolled in RCTs of RA treat-
ments. The main strength of this analysis is that
it was based on a comprehensive SLR. However,
it should be noted that transformation of
median into mean values can introduce bias if
the data summarised by a median value are not
normally distributed [13]. As it was not the aim
of this analysis to evaluate outcomes, the risk of
bias was not assessed. Finally, although a highly
sensitive search strategy with no language or
geographic limits was used, it cannot be guar-
anteed that all relevant studies have been
included.
CONCLUSION
The results of this analysis suggest that the
characteristics of patients included in current
RA clinical trials do not differ from those of
patients included in trials for testing the first
bDMARDs 20 years ago, despite current recom-
mendations for a treat-to-target strategy. Fur-
ther research is needed to determine the impact
of patient characteristics on patients’ response
to RA treatments in clinical trials. It also appears
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15.66 [13.39, 17.93]2010−2017
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Study Mean [95% CI]
(a) Swollen joint count (range 0−66)
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27.35 [25.04, 29.66]
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25.85 [23.68, 28.02]
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28.67 [25.90, 31.43]
14.95 [12.61, 17.29]
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34.60 [31.82, 37.38]
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(b) Tender joint count (range 0−68)
Fig. 4 Forest plots showing means and 95% confidence
intervals (CI; box and whisker plots) for the different
studies according to year of publication for studies
providing data on a swollen joint count (score range
0–66), and b tender joint count (score range 0–68).
Diamond shapes indicate 95% confidence intervals around
the means summarised by timeframe and overall,
respectively. I2 and Tau2 values indicate a high degree of
heterogeneity between studies, while p values indicate no
significant difference in mean scores between studies
published from 1999 to 2009 (studies above dashed line)
and those published from 2010 to 2017 (studies below
dashed line)
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that patients currently being enrolled in RCTs
of RA treatments are not being treated accord-
ing to a treat-to-target strategy before the start
of the study. Future RCTs of RA treatments
should include patients who have been treated
using this strategy if RCTs are to remain infor-
mative and impactful.
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